GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.

Oncology sales rose 94%, driven by strong patient demand for Jemperli, Ojjaara and Zejula. Jemperli added £130 million to GSK’s top line compared with £108 million in second-quarter 2024 ...

GSK is delivering consistent financial performance ... so it's important Jemperli is now available to these patients. Zejula's growth continued in Q3 driven by U.S. pricing effects and high ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

A solid showing for HIV drugs sold by majority-owned ViiV Healthcare and speciality medicines like cancer therapies Zejula ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

GlaxoSmithKline ( (GSK)) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors. GlaxoSmithKline (GSK) is a global biopharmaceutical ...

Legalcategory GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln October 9, 2024 Healthcare & Pharmaceuticalscategory GSK, Pfizer RSV vaccine sales fall in US as millions fewer ...